Entecavir
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (7) | US (FDA) | BARACLUDE | — | 2007-02-23 – 2014-03-20 | fda.gov ↗ |
| Approved | EU (EMA) | Baraclude | — | 2006-06-26 | europa.eu ↗ |
| Approved | US (FDA) | BARACLUDE | — | 2005-03-29 | fda.gov ↗ |
Trials 122 · started per year
Also used as a comparator or background therapy in 124 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT05763576 Background | Apr 2023 → Dec 2024 | chronic hepatitis B virus infection | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1 | NCT04638439 Background | Aug 2022 → Apr 2026 | chronic hepatitis B virus infection, hepatitis D virus infection | PharmaEssentia | Completed | No outcome recorded |
| Phase 1 | NCT05423106 Background | Jul 2022 → Mar 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT05391360 Comparator | Oct 2021 → Jan 2023 | chronic hepatitis B virus infection | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05017116 Background | Aug 2021 → Oct 2023 | chronic hepatitis B virus infection | Suzhou Ribo Life Science Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04536337 Background | Oct 2020 → Jun 2025 | chronic hepatitis B virus infection | Aligos Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03272009 Comparator | Sep 2017 → Jul 2018 | chronic hepatitis B virus infection | Enyo Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02908191 Background | Nov 2016 → Mar 2018 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT02797522 Background | Jun → Nov 2016 | hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT02288208 Background | Nov 2014 → May 2015 | chronic hepatitis B virus infection | TetraLogic Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT01641536 Background | Nov 2011 → Dec 2012 | chronic hepatitis B virus infection | Genexine, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01023230 Background | Sep 2009 → May 2011 | chronic hepatitis B virus infection | Dynavax Technologies Corporation | Completed | No outcome recorded |
| Phase 1/28 trials | ||||||
| Phase 1/2 | NCT06150014 Comparator | Dec 2023 → Dec 2025 overdue | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04536532 Comparator | Oct 2020 → Mar 2023 | chronic hepatitis B virus infection | Sunshine Lake Pharma Co., Ltd. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03109730 Background | Jun 2017 → Mar 2018 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
| Phase 1/2 | NCT02615639 Comparator | Nov 2015 → Nov 2018 | chronic hepatitis B virus infection | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01844063 Background | Jul 2013 → Jan 2016 | liver failure | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02881008 Comparator | Nov 2012 → Oct 2014 | chronic hepatitis B virus infection | Hepatera Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT01718587 Comparator | Nov 2012 → May 2013 | cirrhosis of liver | General Hospital of Chinese Armed Police Forces | Unknown | No outcome recorded |
| Phase 1/2 | NCT01027065 Background | Dec 2009 → Nov 2012 | chronic hepatitis B virus infection | Cytheris SA | Unknown | No outcome recorded |
| Phase 241 trials | ||||||
| Phase 2 | NCT07145268 Comparator | Sep 2025 → Sep 2026 expected | fibrotic liver disease, hepatitis B virus infection | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06990776 Background | Jul 2025 | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 2 | NCT06566248 Comparator | Mar → Sep 2024 | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05484466 Background | Nov → Dec 2022 | chronic hepatitis B virus infection | Shanghai Zhimeng Biopharma, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05275023 Background | Jun 2022 → Dec 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT05382351 Background | May 2022 → Apr 2024 | chronic hepatitis B virus infection | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05256823 Background | Feb 2022 → Nov 2023 | — | Lai Wei | Unknown | No outcome recorded |
| Phase 2 | NCT05808335 Background | Jan 2022 → Mar 2024 | chronic hepatitis B virus infection | ImmuneMed, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05107778 Background | Jan 2022 → Nov 2023 | chronic hepatitis B virus infection | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04820686 Background | May 2021 → Mar 2023 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | No outcome recorded |
| Phase 2 | NCT04585789 Background | Mar 2021 → Feb 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04667104 Background | Feb 2021 → May 2022 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04454567 Background | Nov 2020 → Apr 2021 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | No outcome recorded |
| Phase 2 | NCT04294498 Background | Nov 2020 → Sep 2024 | hepatocellular carcinoma | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04535544 Background | Sep 2020 → Oct 2023 | hepatitis D virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04398134 Background | Aug 2020 → Oct 2021 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | No outcome recorded |
| Phase 2 | NCT04465916 Background | May 2020 → Jun 2021 | chronic hepatitis B virus infection | Enyo Pharma | Terminated | No outcome recorded |
| Phase 2 | NCT04133259 Background | Dec 2019 → Apr 2022 | chronic hepatitis B virus infection | Henlix, Inc | Unknown | No outcome recorded |
| Phase 2 | NCT04189276 Comparator | Dec 2019 → Jun 2021 | hepatitis B virus infection | Tasly Tianjin Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04180150 Background | Nov 2019 → Sep 2020 | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04129554 Background | Nov 2019 → Jul 2021 | chronic hepatitis B virus infection | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 2 | NCT03982186 Background | Aug 2019 → Mar 2021 | chronic hepatitis B virus infection | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 2 | NCT03969017 Background | Jun 2019 → May 2022 | cirrhosis of liver | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03780543 Comparator | Dec 2018 → Apr 2021 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | No outcome recorded |
| Phase 2 | NCT03576066 Background | Jun 2018 → Jul 2019 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
| Phase 2 | NCT03491553 Background | Apr 2018 → Mar 2019 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02862548 Comparator | Sep 2016 → Feb 2018 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02738008 Background | Mar → Dec 2016 | hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02604212 Background | Nov 2015 → Dec 2016 | hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02604199 Background | Sep 2015 → Jan 2017 | chronic hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02452528 Background | Aug 2015 → Dec 2016 | chronic hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02499562 Background | Jun 2015 → Nov 2020 | chronic hepatitis B virus infection | Shanghai Genomics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02391805 Background | May 2015 → Oct 2017 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT02065336 Background | Mar 2014 → Jan 2017 | chronic hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01943799 Background | Sep 2013 → Sep 2014 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01706575 Background | Jan → Sep 2013 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT02726789 Background | Oct 2012 → Sep 2016 | chronic hepatitis B virus infection | Replicor Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01204762 Background | Nov 2010 → Dec 2013 | hepatitis B virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01217632 Background | Aug 2010 → Jun 2015 | fibrotic liver disease | Kyntra Bio | Terminated | No outcome recorded |
| Phase 2 | NCT01242787 Comparator | Aug 2010 → Sep 2012 | chronic hepatitis B virus infection | LG Life Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT01026610 Comparator | Aug 2009 → Nov 2010 | chronic hepatitis B virus infection | LG Life Sciences | Completed | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT07493109 Comparator | May 2026 → Sep 2029 expected | diffuse large B-cell lymphoma | Ou Bai, MD/PHD | Recruiting | No outcome recorded |
| Phase 3 | NCT07095855 Background | Aug 2025 → Jan 2028 expected | chronic hepatitis B virus infection | Shanghai Zhimeng Biopharma, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04051437 Comparator | Aug 2019 → Mar 2020 | chronic liver failure, cirrhosis of liver | Asian Institute of Gastroenterology, India | Unknown | No outcome recorded |
| Phase 3 | NCT04392700 Comparator | Jul 2019 → Jul 2021 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT03236610 Comparator | Jan 2016 → Jun 2018 | — | Uijeongbu St. Mary Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01595685 Comparator | May 2012 → Dec 2014 | chronic hepatitis B virus infection | Asan Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01480284 Comparator | Nov 2011 → Jan 2013 | chronic hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01079806 Comparator | Jun 2010 → Mar 2013 | chronic hepatitis B virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01892241 Comparator | Jan 2010 → Nov 2012 | chronic hepatitis B virus infection | Third Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 3 | NCT00410202 Comparator | Mar 2008 → Jan 2011 | chronic hepatitis B virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00412529 Comparator | Dec 2006 → Feb 2008 | chronic hepatitis B virus infection | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00096785 Comparator | Dec 2004 → Jan 2006 | hepatitis B virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00975091 Comparator | May 2004 → Aug 2007 | chronic hepatitis B virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 428 trials | ||||||
| Phase 4 | NCT07573943 Background | May 2024 → Dec 2026 expected | chronic hepatitis B virus infection | The Second Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT06000657 Comparator | Aug 2023 → Feb 2025 | chronic hepatitis B virus infection | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 4 | NCT05687409 Background | Nov 2019 → May 2021 | cirrhosis of liver, metagonimiasis | First Affiliated Hospital of Zhejiang University | Completed | No outcome recorded |
| Phase 4 | NCT03933384 Comparator | Aug 2019 → Dec 2027 expected | hepatitis B virus infection | Taichung Veterans General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT02945956 Comparator | Apr 2018 → Jun 2020 | portal hypertension | ShuGuang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02945982 Background | Apr 2018 → Jun 2020 | portal hypertension | ShuGuang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03357822 Background | Jan 2018 → Jan 2022 | chronic hepatitis B virus infection | Tongji Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03349008 Background | Nov 2017 → Dec 2019 | chronic hepatitis B virus infection | Cttq | Unknown | No outcome recorded |
| Phase 4 | NCT03308890 Comparator | Nov 2017 → Jul 2019 | chronic hepatitis B virus infection | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT03084250 Comparator | Mar 2017 → Apr 2023 | hepatitis B virus infection | Shanghai Nanhui Nanhua Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03062813 Background | Feb 2017 → Feb 2020 | nephrotic syndrome | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02417207 Comparator | Apr 2015 → Apr 2018 | hepatitis B virus infection | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 4 | NCT02281266 Background | Jan 2015 → Jun 2018 | hepatocellular carcinoma | Jia Fan | Unknown | No outcome recorded |
| Phase 4 | NCT02241590 Comparator | Sep 2014 → Jun 2019 | cirrhosis of liver | ShuGuang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02241616 Background | Sep 2014 → Jun 2019 | cirrhosis of liver | ShuGuang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02097004 Background | Apr 2014 → Jan 2018 | chronic hepatitis B virus infection | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01938820 Background | Jun 2013 → Dec 2016 | cirrhosis of liver | Beijing Friendship Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01938781 Background | Jun 2013 → Dec 2016 | fibrotic liver disease | Beijing Friendship Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01711567 Comparator | Apr 2013 → Dec 2015 | chronic hepatitis B virus infection | Korea University | Completed | No outcome recorded |
| Phase 4 | NCT01829685 Comparator | Mar 2013 → Jun 2016 | chronic hepatitis B virus infection | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT01639092 Comparator | Sep 2012 → Mar 2018 | chronic hepatitis B virus infection | Asan Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01456312 Comparator | Sep 2012 → Feb 2016 | chronic hepatitis B virus infection | Gangnam Severance Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01373684 Comparator | May 2012 → Oct 2019 | chronic hepatitis B virus infection | Foundation for Liver Research | Completed | No outcome recorded |
| Phase 4 | NCT01588912 Comparator | Apr 2012 → Dec 2013 | chronic hepatitis B virus infection | Pusan National University Yangsan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01595633 Background | Mar 2012 → Feb 2014 | chronic hepatitis B virus infection | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT01341743 Comparator | Dec 2010 → Jun 2014 | chronic hepatitis B virus infection | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT01266005 Comparator | Aug 2009 → Aug 2013 | chronic hepatitis B virus infection | Bukwang Pharmaceutical | Terminated | No outcome recorded |
| Phase 4 | NCT00940485 Comparator | Apr 2009 → Dec 2011 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase not applicable22 trials | ||||||
| — | NCT06323681 Comparator | Feb 2024 → Feb 2027 expected | chronic hepatitis B virus infection | Qing XIe | Recruiting | No outcome recorded |
| — | NCT05721300 Background | Feb 2023 → Dec 2024 | chronic hepatitis B virus infection, hepatocellular carcinoma | Zhongshan Hospital (Xiamen), Fudan University | Unknown | No outcome recorded |
| — | NCT05793268 Comparator | Dec 2022 → Dec 2025 overdue | chronic hepatitis B virus infection | E-DA Hospital | Active not recruiting | No outcome recorded |
| — | NCT04199819 Background | Jan 2022 → Dec 2023 | hepatitis B virus infection | The University of Hong Kong | Unknown | No outcome recorded |
| — | NCT05494528 Comparator | May 2021 → Dec 2023 | chronic hepatitis B virus infection | National Taiwan University Hospital | Unknown | No outcome recorded |
| — | NCT04501224 Comparator | Aug 2020 → Oct 2021 | chronic hepatitis B virus infection, cirrhosis of liver | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT04182321 Background | Mar 2020 → Jul 2021 | chronic hepatitis B virus infection | Fu-Sheng Wang | Completed | No outcome recorded |
| — | NCT03920618 Comparator | Feb 2019 → Dec 2024 overdue | hepatitis B virus infection | Third Affiliated Hospital, Sun Yat-Sen University | Recruiting | No outcome recorded |
| — | NCT04196998 Comparator | Jan 2019 → Dec 2023 | cirrhosis of liver, hepatitis B virus infection | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT03771677 Background | Dec 2018 → Dec 2023 | chronic hepatitis B virus infection | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT03568578 Background | Jan 2018 → Dec 2020 | fibrotic liver disease, hepatitis B virus infection | Peking University First Hospital | Unknown | No outcome recorded |
| — | NCT03018821 Background | Jan → Oct 2017 | chronic hepatitis B virus infection | Xi'an Traditional Medicine Hospital | Unknown | No outcome recorded |
| — | NCT03509688 Background | Nov 2014 → Dec 2017 | hepatitis | The First Hospital of Jilin University | Completed | No outcome recorded |
| — | NCT01918631 Comparator | Aug 2013 → Jan 2017 | chronic hepatitis B virus infection | Chinese University of Hong Kong | Completed | No outcome recorded |
| — | NCT01813487 Background | Feb → Jul 2013 | chronic hepatitis B virus infection | Genexine, Inc. | Completed | No outcome recorded |
| — | NCT01599130 Comparator | Jul 2012 → Apr 2014 | chronic hepatitis B virus infection | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT01243281 Comparator | Mar 2011 → May 2013 | chronic hepatitis B virus infection | Chulalongkorn University | Unknown | No outcome recorded |
| — | NCT01083251 Comparator | Mar 2010 → Feb 2012 | chronic hepatitis B virus infection | Ziv Hospital | Unknown | No outcome recorded |
| — | NCT01139203 Comparator | Aug 2009 → Dec 2012 | hepatitis B virus infection | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| — | NCT00931229 Background | Jun 2009 → Dec 2017 | non-Hodgkin lymphoma | National Health Research Institutes, Taiwan | Unknown | No outcome recorded |
| — | NCT01013272 Comparator | Jun 2007 → Jul 2010 | chronic hepatitis B virus infection | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT01018381 Background | Jun 2006 → Jul 2008 | chronic hepatitis B virus infection, hepatocellular carcinoma | The 108 Military Central Hospital | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-09-04 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of Generic Baraclude® Tablets, 0.5mg and 1mg, in the United States tevapharm.com ↗ |
| 2014-06-12 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces U.S. Court of Appeals Upholds Ruling Confirming Invalidity of Baraclude® Patent tevapharm.com ↗ |
| 2008-04-26 | Bristol-Myers Squibb | BARACLUDE® (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients bms.com ↗ |
| 2008-03-24 | Bristol-Myers Squibb | BARACLUDE® (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients bms.com ↗ |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 256 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Entecavir | “A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of a Test Formulation of Entigin Film Coated Tablet 0.5mg (Entecavir 0.5 mg), Compared to an...” NCT02850848 ↗240“Patients will be on their existing nucleosid(t)e analogue therapy comprising lamivudine 100mg daily, adefovir 10mg daily, entecavir 0.5mg or 1.0mg daily or tenofovir 300mg...” NCT01928511 ↗ “Participants will continue on their SOC NrtI, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) tablet QD (once daily) orally as per approved...” NCT03780543 ↗ “First-line NAs (e.g. Entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF)), one tablet a day, take orally,...” NCT06323681 ↗ “NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.” NCT05763576 ↗ “Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)” NCT01943799 ↗ “Oral nucleos(t)ide analogues (NAs) (Entecavir(ETV), Tenofovir disoproxil fumarate tablets(TDF) or Tenofovir Alafenamide Fumarate(TAF)) is used for 12-24 weeks” NCT05182463 ↗ “Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks” NCT05256823 ↗ “Efficacy and Safety of Switching from Entecavir to Tenofovir Alafenamide in Chronic Hepatitis B: A Multicenter Randomized Trial in Korea.” PMID 42015653 ↗ Apr 2026 “The intervention group take entecavir 0.5mg everyday by oral administration for 3 years after hematopoietic stem cell transplantation.” NCT04942886 ↗ “Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert” NCT04454567 ↗ “Other approved antivirals (such as lamivudine, entecavir, or immunoglobulin antihepatitis B) administered per local practice” NCT02862548 ↗ “placebo with nucleos(t)ide analogue (NA) (tenofovir disoproxil fumarate/entecavir) or JNJ-56136379 alone” PMID 36697207 ↗ Jan 2023 “Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg)” NCT01595633 ↗ “either entecavir [ETV], tenofovir disoproxil fumarate [TDF], or tenofovir alafenamide [TAF]” NCT03982186 ↗ “All patients would receive entecavir within 7 days of initiation of durvalumab treatment.” NCT04294498 ↗ “After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)” NCT02586363 ↗ “Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.” NCT01706575 ↗ “Combination therapy (entecavir 0.5 mg once daily plus TAF 25 mg once daily)” NCT07253220 ↗ “patients previously treated with telbivudine will be changed to entecavir” NCT03969017 ↗ “Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg” NCT01597934 ↗ “Brown capsules, each capsule containing 0.53 mg of entecavir hydrate” NCT01480284 ↗ “take one pill of Entecavir(0.5 mg) per day during the study period.” NCT01641536 ↗ “A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al)” NCT01844063 ↗ “2. Entecavir (including salt-free or salt-modifying drugs)” NCT05808335 ↗ “Entecavir Dispersible Tablets, Inhibit viral replication;” NCT06566248 ↗ “tablet entecavir 0.5 mg once daily for hepatitis B” NCT04051437 ↗ “grace entecavir 0.5-1mg per day (oral dose)” NCT01718587 ↗ “such as Entecavir,entecavir 0.5mg per day” NCT03771677 ↗ “Arm B: Entecavir 0.5mg qd for 48 weeks” NCT02474316 ↗ “received entecavir (ETV) for 96 weeks.” NCT05792761 ↗ “T101+ETV(Entecavir) /TDF(Tenofovir)” NCT04189276 ↗ “Entecavir (Baraclude®)” NCT03491553 ↗ “Entecavir (Baraclude)” NCT01373684 ↗ “entecavir 0.5 mg qd” NCT04202653 ↗ “Entecavir (ETV)” NCT04820686 ↗ “Entecavir (ETV)” NCT03576066 ↗ “Entecavir” NCT07573943 ↗ “Entecavir” NCT04133259 ↗ |
| Known as | Baraclude | “This study will examine whether 12 month treatment with entecavir(Baraclude®) has an effect on changes of liver stiffness measurement (LSM) and of hyaluronan measurement in...” NCT01341106 ↗7“All subjects were orally administered once a day at night ： Baraclude® 0.5 mg QD，60weeks” NCT05484466 ↗ “0.5mg Baraclude (entecavir) QD for 6 months after cessation of TDF.” NCT03308890 ↗ “Entecavir (Baraclude) 0.5 mg/day po at week 1-4” NCT00921180 ↗ “Entecavir (Baraclude)0.5 mg/day po at week 1-4” NCT00917761 ↗ “Entecavir (Baraclude®)” NCT03491553 ↗ |
| Known as | Baraclude Tab. | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01913431 ↗ |
| Known as | Baraclude(Entecavir) | “Baraclude(Entecavir)” NCT01641536 ↗ |
| Known as | Cavir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02523547 ↗ |
| Known as | Entecavir (Baraclude) | “Entecavir (Baraclude)” NCT01373684 ↗1“Entecavir (Baraclude)” NCT01023217 ↗ |
| Known as | Entecavir (ETV) | “Entecavir (ETV)” NCT03357822 ↗ |
| Known as | Entecavir (ETV) - brand name Baraclude | “Entecavir (ETV) - brand name Baraclude” NCT03780543 ↗ |
| Known as | Entecavir 0.5mg tablets (Bristol-Myers Squibb) | “Entecavir 0.5mg tablets (Bristol-Myers Squibb)” NCT01894269 ↗ |
| Known as | Entecavir 1.0mg - Braclude | “Entecavir 1.0mg - Braclude” NCT01594905 ↗ |
| Known as | Entecavir dispersible tablets | “Entecavir dispersible tablets is an inhibitor of hepatitis B virus replication.” NCT06990776 ↗1“Entecavir Dispersible Tablets, Inhibit viral replication;” NCT06566248 ↗ |
| Known as | entecavir hydrate | “The study aimed to evaluate the efficacy and safety of tenofovir disoproxil fumarate (TDF) and entecavir hydrate (ETV) in nucleos(t)ide analog (NA)-naïve Japanese chronic...” PMID 28374496 ↗ May 2017 |
| Known as | Entigin | “A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of a Test Formulation of Entigin Film Coated Tablet 0.5mg (Entecavir 0.5 mg), Compared to an...” NCT02850848 ↗ |
| Known as | ETV | “The purpose of our study is to conduct a multicenter, prospective, randomized study comparing the effect of entecavir (ETV) versus LAM for the prevention of HBV reactivation in...” NCT01580202 ↗33“Another potent anti-viral drug, entecavir (ETV), on the other hand, reduces HBV replication in most patients, but causes improvement of liver histology in only 30%, possibly...” NCT01589952 ↗ “First-line NAs (e.g. Entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF)), one tablet a day, take orally,...” NCT06323681 ↗ “NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.” NCT05763576 ↗ “Oral nucleos(t)ide analogues (NAs) (Entecavir(ETV), Tenofovir disoproxil fumarate tablets(TDF) or Tenofovir Alafenamide Fumarate(TAF)) is used for 12-24 weeks” NCT05182463 ↗ “we evaluated the antiviral efficacy and safety of entecavir (ETV) plus tenofovir (TDF) combination therapy in multidrug-resistant (MDR) CHB patients.” PMID 26781724 ↗ Feb 2016 “we conducted a randomized controlled trial in which CHB patients with spontaneous SAE were randomized to receive lamivudine (LVD) or entecavir (ETV)” PMID 28671553 ↗ 2018 “Tenofovir alafenamide (TAF) has emerged as a safe and effective alternative to entecavir (ETV) in the management of chronic hepatitis B (CHB).” PMID 42015653 ↗ Apr 2026 “Participants will also receive background treatment with NA (either tenofovir disoproxil, tenofovir alafenamide [TAF] or entecavir [ETV]).” NCT05275023 ↗ “Switching to Entecavir(ETV) plus Tenofovir Disoproxil Fumarate(TDF) combination will result in faster and greater antiviral activity” NCT01597934 ↗ “Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert” NCT04454567 ↗ “This study explored the efficacy of a novel combination of peg-IFN alfa-2a and entecavir (ETV), a potent nucleoside analogue.” PMID 25190434 ↗ Sep 2014 “Patients were treated with entecavir (ETV) or ETV + thymosin-alpha1 (Thy-α1) or lamivudine (LAM) + adefovir (ADV).” PMID 33460002 ↗ Jan 2021 “Entecavir (ETV) tablet is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection.” NCT04180150 ↗ “The ETV group will receive entecavir (ETV) monotherapy throughout the 96-week treatment course (ETV group).” NCT07345624 ↗ “entecavir (ETV) for 12 weeks with a 48-week course of Peg-IFN starting at week 5 of ETV therapy” PMID 29998882 ↗ Jul 2018 “The patients switched therapy to entecavir (ETV) with or without adefovir (ADV) for 104 weeks.” PMID 33500704 ↗ Jan 2021 “either entecavir [ETV], tenofovir disoproxil fumarate [TDF], or tenofovir alafenamide [TAF]” NCT03982186 ↗ “prophylactic entecavir (ETV) before chemotherapy to 3 months after completing chemotherapy” PMID 23775967 ↗ Jun 2013 “Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.” NCT04196998 ↗ “Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.” NCT04195074 ↗ “Entecavir (0.5mg; ETV) 1 # daily will be used in the prophylactic group.” NCT04405011 ↗ “Entecavir (ETV) is a potent inhibitor of hepatitis B viral replication” PMID 25348661 ↗ Feb 2015 “entecavir (ETV) to peginterferon alfa-2a” PMID 24915612 ↗ Jun 2014 “received entecavir (ETV) for 96 weeks.” NCT05792761 ↗ “Entecavir (ETV) monohydrate” NCT04129554 ↗ “Entecavir (ETV)” NCT05423106 ↗ “Entecavir (ETV)” NCT00065507 ↗ “Entecavir (ETV)” NCT04398134 ↗ “Entecavir (ETV)” NCT07145268 ↗ “entecavir (ETV)” NCT04365933 ↗ “Entecavir (ETV)” NCT00298363 ↗ “entecavir (ETV)” NCT01918631 ↗ |
| Known as | Generic/Brand name: Entecavir/Baraclude(TM) | “Generic/Brand name: Entecavir/Baraclude(TM)” NCT01220596 ↗ |
| Known as | RunZhong | “Patients in the ETV group received ETV tablets (RunZhong, CHIATAI TIANQING, China) 0.5 mg/d orally starting from 2-4 weeks before surgery;” NCT04032860 ↗ |
| Action | Inhibit | “which has been proved effective in suppressing viral replication” NCT00663182 ↗ |
| Modality | Small molecule | “Entecavir, a carbocyclic deoxyguanosine analog” NCT00597259 ↗ |
| Route | Oral | “Tablets, Oral, 1 mg once daily, 96 weeks from the time the last patient is randomized” NCT00065507 ↗ |